Amy Peterson

4.3k citations

41 papers · 3.2k indexed · 3 hit papers · h-index 19

Impact in

Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Hepatology 8
- Liver physiology and pathology 5
- Hepatocellular Carcinoma Treatment and Prognosis 5
Oncology 20
- Cancer Treatment and Pharmacology 6
- Colorectal Cancer Treatments and Studies 4

Co-authors: Thomas F. Gajewski Helena Harlin Yuru Meng Yuanyuan Zha Ian E. Brown Maria Tretiakova Craig L. Slingluff Mark D. McKee
Journals: Journal of Clinical Oncology (15 papers)Cancer Research (5 papers)Clinical Cancer Research (4 papers)Scientific Reports (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States Canada Spain

In The Last Decade

Amy Peterson

41 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer 2013 · 370 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Journal of Clinical Oncology
2009 Cancer Research
2004 Cancer Research

Peers

Countries citing papers authored by Amy Peterson

Since Specialization

Citations

This map shows the geographic impact of Amy Peterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Peterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Peterson more than expected).

Fields of papers citing papers by Amy Peterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Peterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Peterson. The network helps show where Amy Peterson may publish in the future.

Co-authors

The 25 scholars most cited alongside Amy Peterson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amy Peterson Line = papers co-authored together Amy Peterson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Elucidating Mechanisms of Tolerance to Salmonella Typhimurium across Long-Term Infections Using the Collaborative Cross mBio ·W. W., J C Burton, Rachel Lynch, W.G. Preston, Susanne Heinemeyer, Amy Peterson, L. Garry Adams, Michael Kirby, David W. Threadgill, Helene Andrews‐Polymenis	2022	6
2	Pathway expression analysis Scientific Reports ·Rifqi Ridlo Phahlevy, F.V. Cappadonna, Amy Peterson, Michael Kirby	2022	5
3	Genetic background influences survival of infections with Salmonella enterica serovar Typhimurium in the Collaborative Cross PLoS Genetics ·W. W., Rachel Lynch, J C Burton, W.G. Preston, P. Rajakone, Clinton J. Steketee, Kooshan Moradi, Susanne Heinemeyer, Amy Peterson, L. Garry Adams, Michael Kirby, David W. Threadgill, Helene Andrews‐Polymenis	2022	9
4	Early prognosis of respiratory virus shedding in humans Scientific Reports ·Susanne Heinemeyer, Emad Bukhari, Amy Peterson, Angela L. Rasmussen, Nirce Saffer Medvedovski, Pabasara Wijeratne, Michael Kirby	2021	5
5	The Gaussian limit for high-dimensional spherical means Journal of Functional Analysis ·Amy Peterson, Ambar N. Sengupta	2018	1
6	A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer Clinical Cancer Research ·Lee S. Schwartzberg, Denise A. Yardley, Anthony Elias, Manish R. Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy Peterson, Martha Blaney, Joyce Steinberg, Jacqueline A. Gibbons, Tiffany A. Traina	2017	42
7	Pronogrady, not fast speed specifically, acts as a constraint on vertebral formula in mammals Milena R. Shattuck, Lauren Petrullo, Amy Peterson, T Natschev, みゆ紀坂東, Zainab Lateef Abbass, Sabu Paul	2017	1
8	Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Michael J. Morris, Dana E. Rathkopf, William Novotny, Jacqueline A. Gibbons, Amy Peterson, Zakaria Khondker, Taoufik Ouatas, Howard I. Scher, Mark T. Fleming	2016	22
9	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Clinical Cancer Research ·Ravi Salgia, Premal H. Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Catenacci, Amy Peterson, Mark J. Ratain, Blasé N. Polite, Janice M. Mehnert, Rebecca A. Moss	2014	56
10	HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors Molecular Cancer Therapeutics ·Elicia Penuel, Congfen Li, 秀夫大津, Luciana Burton, Kyra J. Cowan, Mark Merchant, Robert L. Yauch, Premal H. Patel, Amy Peterson, Garret M. Hampton, Mark R. Lackner, Priti S. Hegde	2013	20
11	Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development Clinical Cancer Research ·Hong Xiang, Brendan C. Bender, Arthur E. Reyes, Mark Merchant, Nelson L. ‘Shasha’ Jumbe, Mally Romero, Yicheng Qiu, Ihsan Nijem, Elaine Mai, Judy Young, Amy Peterson, Lisa A. Damico‐Beyer	2013	28
12	Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer. Journal of Clinical Oncology ·Mark T. Fleming, Dana E. Rathkopf, Fernando Ascanio-Gosling, Amy Peterson, Alison L. Hannah, David Forer, Howard I. Scher, Michael J. Morris	2013	2
13	Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections Mucosal Immunology ·Nydiaris Hernández‐Santos, Anna R. Huppler, Amy Peterson, Shabaana A. Khader, Kyle C. McKenna, Sarah L. Gaffen	2012	147
14	Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Journal of Clinical Oncology ·David R. Spigel, Thomas J. Ervin, Rodryg Ramlau, თამთა გრიგოლია, Jerome H. Goldschmidt, G. R. Blumenschein, Maciej Krzakowski, G. Robinet, Christelle Clément-Duchêne, Fabrice Barlési, Ramaswamy Govindan, Taral Patel, С. В. Орлов, M. S. Wertheim, J. Zha, Ajay Pandita, Wenjing Yu, Robert L. Yauch, Premal H. Patel, Amy Peterson	2011	149
15	Role of MetMAb (OA-5D5) in c-MET active lung malignancies Expert Opinion on Biological Therapy ·Harley C. Shands, Premal H. Patel, Amy Peterson, Ravi Salgia	2011	37
16	Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment Cancer Research ·Helena Harlin, Yuru Meng, Amy Peterson, Yuanyuan Zha, Maria Tretiakova, Craig L. Slingluff, Mark D. McKee, Thomas F. Gajewski Hit paper breakdown →	2009	872
17	The HLA‐A2‐restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer The Prostate ·Albert Mjong-Tschol Kim, Amy Peterson, Brian I. Rini, Helena Harlin, Thomas F. Gajewski, Walter M. Stadler	2008	9
18	Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites Cancer Immunology Immunotherapy ·Helena Harlin, María del Rosario Baquero Mesa, Amy Peterson, Yuru Meng, Thomas F. Gajewski	2006	111
19	T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-α Nature Immunology ·Yuanyuan Zha, Reinhard Marks, Allen W. Ho, Amy Peterson, Бережнова Елена Ивановна, Ian E. Brown, Kesavannair Praveen, Stacey L. Stang, James C. Stone, Thomas F. Gajewski	2006	221
20	T cell development and function in CrkL‐deficient mice European Journal of Immunology ·Amy Peterson, Reinhard Marks, Patrick E. Fields, Akira Imamoto, Thomas F. Gajewski	2003	14

About Amy Peterson

Amy Peterson is a scholar working on Hepatology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Immunology, having authored 41 papers that have together received 3.2k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (10 papers), Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (6 papers), Liver physiology and pathology (5 papers), Immunotherapy and Immune Responses (5 papers), Lung Cancer Treatments and Mutations (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Immunology (1.6k citations), Oncology (1.9k citations), Hepatology (341 citations), Pulmonary and Respiratory Medicine (702 citations) and Cancer Research (311 citations). Amy Peterson has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Thomas F. Gajewski, Helena Harlin, Yuru Meng, Yuanyuan Zha, Ian E. Brown, Maria Tretiakova, Craig L. Slingluff, Mark D. McKee, M.T. Spiotto and Yoshiko Iwai. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Scientific Reports and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact